Does Depakote Cause Hypertension?
No, Depakote (valproic acid/valproate) does not cause hypertension—in fact, the opposite is true: hypertension is listed as a rare adverse effect (1-5% incidence) in controlled trials, but emerging evidence suggests valproate may actually have antihypertensive properties. 1
Evidence from FDA Drug Labeling
The official FDA prescribing information for Depakote lists hypertension among cardiovascular adverse reactions reported in greater than 1% but less than 5% of patients in controlled trials of complex partial seizures 1. However, this low incidence does not establish causation, particularly given the context of other medications and underlying conditions in these patients.
Importantly, the FDA label also documents that in status epilepticus treatment, valproate may have contributed to hypotension in some patients, not hypertension 2. One case series found that IV valproate loading in patients with cardiovascular instability and hypotension was well tolerated 2.
Contradictory Case Report
There is one isolated case report from 2016 describing an 8-year-old boy who developed hypertensive urgency after valproate initiation, which resolved upon discontinuation 3. This represents a single pediatric case and stands in stark contrast to the broader evidence base.
Emerging Evidence: Valproate as Antihypertensive
Multiple recent research studies suggest valproate may actually lower blood pressure:
High-fat diet-induced hypertension: Valproate prevented progression of hypertension in mice by downregulating the renin-angiotensin system via HDAC1 inhibition 4
L-NAME-induced hypertension: Valproate supplementation normalized mean arterial pressure and attenuated hypertension in rats 5
Spontaneously hypertensive rats: Valproate reduced blood pressure through epigenetic modifications affecting TRH gene expression, with transgenerational effects 6
Acute kidney injury model: Valproate prevented AKI-provoked hypertension in rats 7
Clinical Context and Metabolic Considerations
While valproate is associated with metabolic effects including weight gain, insulin resistance, and polycystic ovary disease 8, a cross-sectional study of 200 institutionalized patients found that valproate plus antipsychotics did not significantly increase the prevalence of hypertension compared to antipsychotics alone 9.
Clinical Recommendation
Monitor blood pressure in patients on valproate as part of routine care, but do not avoid or discontinue valproate due to concerns about causing hypertension. If hypertension develops in a patient on valproate:
- Evaluate other contributing factors (weight gain, other medications, underlying conditions)
- Consider that valproate is unlikely to be the primary cause
- The single pediatric case report 3 suggests rare idiosyncratic reactions are theoretically possible, but this should not drive clinical decision-making
Common pitfall: Attributing hypertension to valproate when metabolic syndrome components (obesity, insulin resistance) are the actual culprits. Weight gain from valproate may indirectly contribute to hypertension through metabolic pathways, but this is distinct from direct drug-induced hypertension.